Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat and Azacitidine Combined With CHOP vs CHOP in Untreated Peripheral T-cell Lymphoma
NCT05075460Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucidinostat, azacitidine in peripheral T-cell lymphoma (PTCL), sponsored by Peking Union Medical College Hospital. Started Oct 2021; status: recruiting.
02
Drugs
tucidinostatazacitidine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05075460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075460.